A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 2, 2010, Pages 299-306

  Moe, Sharon M ^a,b   Saifullah, Akber ^a   LaClair, Robert E ^a   Usman, Sohail A ^a   Yu, Zhangsheng ^a  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; DOXERCALCIFEROL; PARATHYROID HORMONE; VITAMIN D;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SINGLE BLIND PROCEDURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGED; BIOLOGICAL MARKERS; CALCIUM; CHOLECALCIFEROL; CHRONIC DISEASE; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 77749334653     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07131009     Document Type: Article

References (33)

1. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K: Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3: 1144-1151, 2008
2. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM: Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-1033, 2005
3. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR: Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30: 771-777, 2002
4. Elder GJ, Mackun K: 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 21: 1778-1784, 2006
5. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol, 24: 503-510, 2004
6. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
7. Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ: Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton) 13: 63-67, 2008
8. Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H: Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in nondiabetic predialysis CKD patients. Bone, 44: 678-683, 2009
9. Gutierrez OM, Isakova T, Andress DL, Levin A, Wolf M: Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 73: 956-962, 2008
10. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G: Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 294: 2336-2341, 2005
11. Adami S, Viapiana O, Gatti D, Idolazzi L, Rossini M: Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 42: 267-270, 2008
12. Fadem SZ, Moe SM: Management of chronic kidney disease-mineral bone disorder. Adv Chronic Kidney Dis 14: 2, 2007
13. Hewison M, Zehnder D, Bland R, Stewart PM: 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol 25: 141-148, 2000
14. Brown AJ, Ritter CS, Knutson JC, Strugnell SA: The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant, 21: 644-650, 2006
15. K/DOQI, NKF: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
16. KDIGO: Clinical practice guidelines for the management of CKD-MBD. Kidney Int 76: S1-S130, 2009
17. Stergiou GS, Skeva II, Zourbaki AS, Mountokalakis TD: Self-monitoring of blood pressure at home: How many measurements are needed? J Hypertens 16: 725-731, 1998
18. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157: 2413-2446, 1997
19. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajagopalan S, Port FK, Wolfe RA, Saran R: Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45: 658-666, 2005
20. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877-890, 2004
21. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ: Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50: 59-68, 2007
22. Zisman AL, Hristova M, Ho LT, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 36-43, 2007
23. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V: Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study. Endocr Pract 14: 10-17, 2008
24. Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferriere C, Bedrossian J, DeLuca HF: Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int, 15: 196-204, 1979
25. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis, 50: 69-77, 2007
26. Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y: Alterations in serum levels of 1 alpha,25(OH)2 D3 and osteocalcin in patients with early diabetic nephropathy. Diabetes Res Clin Pract, 38: 53-59, 1997
27. Verrotti A, Basciani F, Carle F, Morgese G, Chiarelli F: Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest, 22: 198-202, 1999
28. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK: Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: An uncontrolled trial. Am J Kidney Dis 51: 724-731, 2008
29. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 52: 249-255, 2008
30. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005
31. Zeeuw D, Agarwal R, Amdahl M, Andress D, Audhya P, Coyne D, Garimella T, Parving H, Pritchett Y, Remuzzi G, Ritz E: Selective vitamin D receptor activator (VDRA) for albuminuria lowering (VITAL) study in type 2 diabetic nephropathy. Presented at the Annual Meeting of the American Society of Nephrology, San Diego, CA, October 20, 2009
32. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86: 1633-1637, 2001
33. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, Beresford SA, Connelly SA, Curb JD, Grimm RH, Jr., Kotchen TA, Kuller LH, Wassertheil-Smoller S, Thomson CA, Torner JC: Effect of calcium and vitamin D supplementation on blood pressure: The Women's Health Initiative Randomized Trial. Hypertension 52: 847-855, 2008